NCT03009019 - Efficacy, Tolerability, and Safety of DFN-15 | Biotech Hunter

Enrollment

631

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

November 30, 2017

Study Completion Date

May 31, 2019

Conditions

Migraine Headache

Interventions

DRUG

DFN-15 Active

OTHER

DFN-15 Placebo

Trial Locations (43)

11229

Site 645, Brooklyn

14609

Site 608, Rochester

23294

Site 635, Richmond

27262

Site 620, High Point

28117

Site 643, Mooresville

29464

Site 639, Mt. Pleasant

30034

Site 625, Decatur

30328

Site 630, Sandy Springs

32763

Site 641, Orange City

32801

Site 629, Orlando

33176

Site 603, Miami

33409

Site 601, West Palm Beach

35205

Site 609, Birmingham

36608

Site 640, Mobile

40213

Site 602, Louisville

44122

Site 628, Cleveland

48104

Site 634, Ann Arbor

55435

Site 623, Edina

57049

Site 612, Dakota Dunes

58103

Site 626, Fargo

59808

Site 606, Missoula

60406

Site 604, Blue Island

63303

Site 638, City of Saint Peters

68134

Site 613, Omaha

70115

Site 644, New Orleans

70124

Site 610, New Orleans

71901

Site 616, Hot Springs

75231

Site 611, Dallas

78240

Site 632, San Antonio

78745

Site 627, Austin

80127

Site 631, Littleton

83642

Site 642, Meridian

84123

Site 621, Taylorsville

85745

Site 622, Tucson

87102

Site 636, Albuquerque

92078

Site 624, San Marcos

92108

Site 646, San Diego

92647

Site 637, Huntington Beach

94102

Site 619, San Francisco

94607

Site 615, Oakland

03756

Site 647, Lebanon

03060

Site 618, Nashua

02886

Site 614, Warwick